Treatment of type 2 diabetes through beta cell protection
| Reference number | |
| Coordinator | Abarceo AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | May 2018 - November 2018 |
| Status | Completed |
| Venture | Innovative Startups |
Purpose and goal
Abarceo AB was granted funding for the validation of whether Arc01treatment may have beneficial effects at later stages of diabetes in a type 2 diabetes mouse model. A preliminary study was conducted to optimize solubility for oral administration. Pharmacokinetics were investigated to establish the relationship between dose and exposure. The results showed good oral bioavailability. A contract research lwill complete the study by January 15, 2019. As the results of this study are not yet available, we can not report the outcome of this last study.
Expected results and effects
The companies presented to Abarceo have expressed interest in continued cooperation if we can show that treatment is really disease-modifying. Since the animal study is funded by a pharmaceutical company, we have had the opportunity to expand the study to investigate more parameters. Should the results of the study show beneficial effects, ongoing collaboration discussions will proceed to the next level with the pharmaceutical company in question.
Planned approach and implementation
In January 2019, we will have an answer as to whether the proposed treatment is disease-modifying also in a long-term and durable manner. If so, we will have verified that blocking the target molecule on the cell surface of beta cells has real potential to respond to a major need in type 2 diabetes patients, namely disease modifying therapy that can stop or reverse type 2 diabetes.